Opioids and GI Motility-Friend or Foe?

Overview

Journal Curr Treat Options Gastroenterol

Specialty Gastroenterology

Date 2016 Nov 4

PMID 27807793

Citations 13

Authors

Allen A Lee

William L Hasler

Affiliations

Soon will be listed here.

Abstract

The use of opioids for the treatment of chronic non-cancer pain is growing at an alarming rate. Opioid-induced bowel dysfunction (OBD) is a common adverse effect of long-term opioid treatment manifesting as constipation, nausea, and vomiting. These effects are primarily mediated by peripheral μ-opioid receptors with resultant altered GI motility and function. As a result, patients may present with opioid-induced constipation (OIC), opioid-induced nausea and vomiting (OINV), and/or narcotic bowel syndrome (NBS). This often leads to decreased quality of life and in many cases, discontinuation of opioid therapy. There is limited evidence to support the use of traditional anti-emetics and laxatives in the treatment of OBD. Tapering the dose of opioids, switching to transdermal application, opioid rotation, or dual-action opioids, such as tapentadol, may be helpful in the treatment of OBD. Novel agents, such as peripherally acting μ-opioid receptor antagonists which target the cause of OIC, show promise in the treatment of OBD and should be considered when conventional laxatives fail. This chapter will review the pathophysiology of OBD, including OINV and OIC, and treatment options available.

Citing Articles

Could chronic opioid use be an additional risk of hepatic damage in patients with previous liver diseases, and what is the role of microbiome?.

Tarantino G, Cataldi M, Citro V Front Microbiol. 2024; 15:1319897.

PMID: 39687876 PMC: 11646994. DOI: 10.3389/fmicb.2024.1319897.

Comparison of Efficacy and Safety of Prophylactic Use of Metoclopramide and Haloperidol on Morphine-induced Nausea and Vomiting in Cancer Patients: A Comparative, Randomised, Prospective Study.

Singhal Y, Pingoliya S, Saji S, Gaurav R Indian J Palliat Care. 2024; 30(4):375-379.

PMID: 39650588 PMC: 11618674. DOI: 10.25259/IJPC_141_2024.

Ing Lorenzini K, Wainstein L, Spechbach H, Sarasin F, Ramlawi M, Desmeules J Pharmacol Res Perspect. 2022; 10(6):e01033.

PMID: 36404650 PMC: 9676686. DOI: 10.1002/prp2.1033.

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial.

Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y Cancers (Basel). 2022; 14(9).

PMID: 35565243 PMC: 9102438. DOI: 10.3390/cancers14092112.

Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response.

Golusda L, Kuhl A, Siegmund B, Paclik D Inflamm Bowel Dis. 2021; 28(5):801-807.

PMID: 34871378 PMC: 9074866. DOI: 10.1093/ibd/izab290.

References

Ahmedzai S, Brooks D . Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage. 1997; 13(5):254-61. DOI: 10.1016/s0885-3924(97)00082-1. View

Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer M . Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008; 9(10):883-91. DOI: 10.1016/j.jpain.2008.05.005. View

Crain S, Shen K . Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci. 1990; 11(2):77-81. DOI: 10.1016/0165-6147(90)90322-y. View

Iasnetsov V, Drozd I, Shashkov V . [Emetic and antiemetic properties of regulatory peptides]. Biull Eksp Biol Med. 1987; 103(5):586-8. View

Siemens W, Becker G . Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. Ther Clin Risk Manag. 2016; 12:401-12. PMC: 4795449. DOI: 10.2147/TCRM.S80749. View

Manchikanti L, Singh A . Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008; 11(2 Suppl):S63-88. View

Grace P, Maier S, Watkins L . Opioid-induced central immune signaling: implications for opioid analgesia. Headache. 2015; 55(4):475-89. PMC: 4402135. DOI: 10.1111/head.12552. View

Drossman D, Szigethy E . The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl. 2014; 2(1):22-30. DOI: 10.1038/ajgsup.2014.6. View

Davis M, Hallerberg G . A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 2010; 39(4):756-67. DOI: 10.1016/j.jpainsymman.2009.08.010. View

10.

Candy B, Jones L, Goodman M, Drake R, Tookman A . Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011; (1):CD003448. DOI: 10.1002/14651858.CD003448.pub3. View

11.

Armstrong S, Campbell C, Richardson C, Vickery R, Tsuruda P, Long D . The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386(6):471-8. DOI: 10.1007/s00210-013-0844-5. View

12.

Finco G, Pintor M, Sanna D, Orru G, Musu M, De Conno F . Is target opioid therapy within sight?. Minerva Anestesiol. 2012; 78(4):462-72. View

13.

Lange B, Kuperwasser B, Okamoto A, Steup A, Haufel T, Ashworth J . Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27(6):381-99. DOI: 10.1007/s12325-010-0036-3. View

14.

Kovac A, Eberhart L, Kotarski J, Clerici G, Apfel C . A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 2008; 107(2):439-44. DOI: 10.1213/ane.0b013e31817abcd3. View

15.

Yates B, Miller A, Lucot J . Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull. 1999; 47(5):395-406. DOI: 10.1016/s0361-9230(98)00092-6. View

16.

Manchikanti L, Abdi S, Atluri S, Balog C, Benyamin R, Boswell M . American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012; 15(3 Suppl):S67-116. View

17.

Allan L, Hays H, Jensen N, de Waroux B, Bolt M, Donald R . Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001; 322(7295):1154-8. PMC: 31593. DOI: 10.1136/bmj.322.7295.1154. View

18.

Chamberlain B, Cross K, Winston J, Thomas J, Wang W, Su C . Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009; 38(5):683-90. DOI: 10.1016/j.jpainsymman.2009.02.234. View

19.

Bagnol D, Mansour A, Akil H, Watson S . Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997; 81(2):579-91. DOI: 10.1016/s0306-4522(97)00227-3. View

20.

Scotto di Fazano C, Vergne P, Grilo R, Bertin P, Bonnet C, Treves R . [Preventive therapy for nausea and vomiting in patients on opioid therapy for non-malignant pain in rheumatology]. Therapie. 2003; 57(5):446-9. View